Screener Summaries Updates Institutions Sign In More Updates › Dividends & Buybacks › CRIS Dividends & Buybacks · Jul 1, 2026
On June 25, 2026, Curis, Inc. stockholders approved amendments to the Restated Certificate of Incorporation allowing… CRIS Curis Inc
On June 25, 2026, Curis, Inc. stockholders approved amendments to the Restated Certificate of Incorporation allowing for a reverse stock split. Following this approval, the Board of Directors implemented a 1-for-20 reverse stock split of the company's issued and outstanding common stock. Curis, Inc. is a biotechnology company that develops therapeutics for the treatment of cancer.
More from Curis Inc Nasdaq notifies Curis of non-compliance with the $1.00 minimum bid price requirement Nov 6, 2026 Curis raises $8.5M in equity offering at $0.51 per share to fund CLL research Oct 19, 2026 Curis, Inc. received written notice from the Nasdaq Stock Market LLC on July 24, 2026, confirming that it has regained… Jul 30, 2026 Curis, Inc. implemented a 1-for-20 reverse stock split of its issued and outstanding common stock, effective July 2… Jul 2, 2026 Curis, Inc. announced that its reverse stock split is expected to become effective on July 2, 2026, at 5:00 PM ET Jul 1, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
